The National Institute for Health and Care Excellence (NICE) has published a suite of guidance to support health professionals during the COVID-19 outbreak. We have reviewed this guidance and summarised the most relevant for our nurses. Check them out below:
The purpose of this guideline is to maximise the safety of patients who need critical care during the COVID-19 pandemic while protecting staff from infection. NICE has developed a critical care referral algorithm to support decision making. Read more here.
Delivery of systemic anti-cancer treatments
The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources while protecting staff from infection. Read more here.
Managing symptoms (including end of life) in the community
The purpose of this guidance is to provide recommendations for managing COVID-19 symptoms for patients in the community, including at the end of life. It also includes recommendations about managing medicines for these patients and protecting staff from infection. Read more here.
Managing pneumonia in adults (community)
The purpose of this guideline is to ensure the best treatment for adults with suspected or confirmed pneumonia in the community during the COVID-19 pandemic. Read more here.
Adults and children with severe asthma
The purpose of this guideline is to maximise the safety of adults and children with severe asthma during the COVID-19 pandemic, while protecting staff from infection. Read more here.
The purpose of this guideline is to maximise the safety of patients with cystic fibrosis and make the best use of NHS resources, while protecting staff from infection. Read more here.
The purpose of this guideline is to maximise the safety of patients with Chronic Obstructive Pulmonary Disease (COPD) during the COVID-19 pandemic, while protecting staff from infection. Read more here.
Patients with dermatological conditions
The purpose of this guideline is to maximise the safety of children and adults who have dermatological conditions treated with drugs affecting the immune response during the COVID-19 pandemic. Read more here.
Patients with rheumatological conditions
The purpose of this guideline is to maximise the safety of children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic. Read more here.
Patients with patients with gastrointestinal and liver conditions
The purpose of this guideline is to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID-19 pandemic. Read more here.
Patients with Acute Myocardial Injury
The purpose of this guideline is to help healthcare professionals who are not cardiology specialists identify and treat acute myocardial injury and its cardiac complications in adults with known or suspected COVID-19 but without known pre-existing cardiovascular disease. Read more here.
Patients with Interstitial Lung Disease
The purpose of this guidance is to maximise the safety of adults with interstitial lung disease, including idiopathic pulmonary fibrosis, and pulmonary sarcoidosis during the COVID-19 pandemic. Read more here.
Patients with Chronic Kidney Disease
The purpose of this guidance is to maximise the safety of adults with interstitial lung disease, including idiopathic pulmonary fibrosis, and pulmonary sarcoidosis during the COVID-19 pandemic. Read more here.
